

Strategic Partner Group Prospectus

For Veterinary Facilities Expanding into Human Diagnostic Testing

1. Overview

Strategic Partner Group (SPG) is a global consortium and investment facilitator connecting **veterinary laboratories, animal health facilities, and biotech ventures** with strategic investors and funding sources to accelerate their transition into **human diagnostic testing** — including **PCR, genetic, and biosurveillance platforms**.

SPG supports facilities seeking **\$5 million to \$200 million+** to modernize infrastructure, acquire testing technology, and enter the human diagnostics and healthcare markets through joint ventures, licensing, or research-based expansion.





“SPG bridges veterinary science and human health — advancing global diagnostic capability through strategic capital and partnerships.”


2. Why Partner with SPG

Veterinary and animal diagnostic facilities already possess much of the infrastructure, scientific expertise, and compliance processes necessary for human diagnostics.

SPG helps bridge the **funding, partnership, and regulatory pathway** to expand into human testing and clinical diagnostics.

Partner Benefits

-  *Expand to Human Diagnostics:* Secure capital for PCR, molecular, and clinical testing infrastructure.
-  *Access Institutional & Healthcare Capital:* Tap into a network of global investors focused on biotech and healthcare convergence.
-  *Diversify Revenue Streams:* Add human diagnostic services alongside veterinary operations.
-  *Global Partnership Integration:* Collaborate with international research, hospital, and technology partners.

-  *Compliance & Transition Strategy*: Navigate certification and FDA/CLIA readiness through strategic alignment.
-

3. Core Service Pillars

A. Capital Access & Investor Facilitation

- Funding from **\$5M–\$200M+** for facility expansion, testing equipment, and certification upgrades
- Access to healthcare and biotech investors, family offices, and venture capital funds
- Joint venture facilitation for cross-sector partnerships between veterinary and human health entities

B. Laboratory Transformation & Technology Integration

- Expansion from veterinary testing to human diagnostics (PCR, DNA/RNA sequencing, clinical chemistry)
- Acquisition or licensing of human diagnostic technology and systems
- Partnerships for co-located or shared testing facilities

C. Investment Packaging & Strategic Structuring

- Preparation of investor-ready proposals and valuation models
- Structuring equity, debt, or blended financing tailored for healthcare expansion
- Guidance on compliance frameworks and certification pathways

D. Consortium & Partnership Development

- Creation of **Veterinary–Human Health Diagnostic Consortia** under SPG’s umbrella
- Collaboration with global medical networks and research universities
- Establishment of public–private partnerships (PPP) for bio-surveillance and testing infrastructure


4. Veterinary to Human Testing Transition Model





Stage	Partner Role	SPG Role	Outcome
Discovery	Identify interest in human diagnostic expansion	Evaluate market fit & readiness	Funding & compliance roadmap
Preparation	Provide lab capabilities & financial data	Develop investor documentation	Investor-grade presentation
Introduction	Maintain facility operations	Facilitate investor and partner introductions	Aligned capital partners
Execution	Oversee facility expansion	Manage negotiation, compliance, and project execution	Operational human diagnostic division

5. Target Partners & Use Cases

- Veterinary laboratories expanding to human diagnostic testing
 - Research and bioscience facilities launching dual-use platforms
 - University-affiliated animal labs upgrading to FDA/CLIA-certified facilities
 - Rural or regional veterinary clinics adding human testing for underserved populations
 - Facilities entering **public health, biosecurity, or disease surveillance** programs
-

6. The SPG Advantage

-  **Global Investor Access** — Private equity, venture capital, and healthcare consortium funding

-  **Cross-Sector Expertise** — Bridging animal health, human diagnostics, and biotech innovation
 -  **Strategic Structuring** — Turnkey funding and compliance-ready execution support
 -  **Innovation Alignment** — Backing transformative diagnostic projects with sustainable frameworks
 -  **Operational Partnerships** — Co-branded opportunities with labs, universities, and medical groups
-

7. Leadership

Sam Jacobs, President — Global investment strategist with \$500M+ in structured funding initiatives in healthcare, biotech, and infrastructure.

Rick Reese, Operations Director — Senior consultant with 35 years of experience in business development, procurement, and alternative finance, leading healthcare and biotech project partnerships across multiple continents.

8. Engagement Process


1. Schedule an SPG diagnostic sector introduction call.
2. Share your facility overview and expansion vision.
3. SPG prepares a tailored investor and partnership package.
4. We facilitate qualified introductions to investors and consortium partners.


5. Funding and project implementation under SPG's oversight.


Contact

Strategic Partner Group (SPG)

 www.strategicpartnergroup.com

 info@strategicpartnergroup.com

 +1 (516) 880-4707

 Global Headquarters: New York, USA

Outreach Email for Veterinary Facilities Expanding to Human Testing

Subject: Expand Your Veterinary Facility into Human Diagnostics — Access \$5M–\$200M+ in Funding

Body:

Dear [Name],

I'm reaching out to introduce **Strategic Partner Group (SPG)** — a global consortium that helps **veterinary and diagnostic facilities** secure funding and strategic partnerships for expansion into **human testing and clinical diagnostics**.

SPG connects laboratories and medical innovators with institutional investors and healthcare partners to help scale PCR, genetic, and diagnostic operations globally.

Our focus includes:

- Funding from **\$5 million to \$200 million+** for facility expansion and human testing conversion
- Partnerships for **PCR, molecular, and biosurveillance testing**
- Strategic alignment with hospitals, universities, and healthcare consortiums
- Assistance with **FDA/CLIA compliance** and investment packaging
- Full transaction management from funding to operational launch

If your facility is considering expansion into human diagnostic testing or seeking capital for modernization, SPG can help you navigate funding and partnership pathways globally.

Would you be open to a short conversation about potential collaboration?


Warm regards,

Sam Jacobs

President | Strategic Partner Group

 info@strategicpartnergroup.com

 www.strategicpartnergroup.com

 +1 (516) 880-4707